5 min read
The Delta Variant Furin Domain Mutation Favors Greater Infectivity
The Delta variant has quickly become the predominant strain of SARS-CoV-2. Based on molecular modeling studies,...
6 min read
Functional Assays: Narrowing the Field from Binders to Therapeutic Candidates
Candidate ID: How to go from hits to lead candidates
We tend to think of antibodies as being defined by their...
1 min read
Original Research: Targeting Three Spike Protein Domains Regulating SARS-CoV-2 Infectivity
Like our research colleagues across the entire global scientific community, our team here at Antibody Solutions...
4 min read
Peptides: The Less-is-More Strategy for Success
A strategic approach to peptide design yields success
When deciding which antigens to use for an antibody discovery...
7 min read
Animals are Still Vital for Antibody Discovery
If the last year has taught us anything, it’s that major biological threats can emerge seemingly out of nowhere,...
4 min read
Getting your antigen to stand out in the crowd
Here at Antibody Solutions, we believe that starting with the best possible input will yield the best possible output....
5 min read
Cell Fusion: A trusted tool that can still be an enigma
“Mystery is at the heart of creativity. That, and surprise.” Julia Cameron
Hybridoma Cell Fusion 101 When it comes to...
2 min read
Modeling the Impact of the UK and South African Strain Mutations
Mutations Found in the South African and UK COVID-19 Virus Strains Improve the Stability of the ACE2-Spike RBD Complex
5 min read
Measure Twice, Cut Once: The Value of Target Analysis in Antibody Discovery
Editor’s note: Welcome to 2021, and to our first in a year-long series of posts that will explore the essentials in...
2 min read
The UK Strain and Other Recent RBD Mutations in the SARS-CoV-2 Virus
Examining mutations in the SARS-CoV-2 Spike (S) Protein Receptor Binding Domain (RBD) at the ACE2 receptor S protein...
5 min read
COVID-19 Targets, Tools and Therapeutics (Part 2)
Antibody Solutions is doing its part to respond to the COVID-19 pandemic, including original research, tool discovery,...
4 min read
Expanding the Repertoire of Antibody Drug Discovery with Lambda Light-Chain Models
Accessing the Untapped Potential of 33% of Human IgG
Harvard economist Michael Porter, PhD offers a clever observation...
3 min read
Global Spotlight Shines on mRNA Thanks to Pfizer, BioNTech COVID-19 Vaccine Candidate
In the science shot heard ‘round the world, Pfizer and BioNTech announced Monday that their vaccine candidate (aka...
3 min read
COVID-19 Targets, Tools and Therapeutics (Part 1)
Antibody Solutions is doing its part to respond to the COVID-19 pandemic, including original research, tool discovery,...
Filter by Keyword
- Insights (29)
- COVID-19 (13)
- Covid (13)
- SARS-CoV-2 (12)
- Molecuar Modeling (9)
- News (9)
- Events (8)
- Transgenic Animals (5)
- antibody discovery (4)
- Therapeutic Targets (3)
- 25th Anniversary (2)
- therapeutic monoclonal antibodies (2)
- CAR-T (1)
- Cell therapy (1)
- Functional Assays (1)
- Harbour (1)
- Hybridoma (1)
- IgG purification (1)
- Lambda Mouse (1)
- MAbExpress (1)
- Monoclonal (1)
- OmniRat (1)
- antigen (1)
- cell fusion (1)
- igG (1)
- immunoassays (1)
- immunogens (1)
- lambda light chain (1)
- mRNA (1)
- peptides (1)
- syngeneic (1)
- target analysis (1)
- transgenic H2L2 mice (1)
- women in bio (1)